COX-2 inhibitors and the thrombotic risk.
Schrör
Karsten
K
Weber
Artur-Aron
AA
D000818:Animals; D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D015232:Dinoprostone / Q000378:metabolism; D011464:Epoprostenol / Q000378:metabolism; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000378:metabolism; D018570:Risk Assessment; D013927:Thrombosis / Q000139:chemically induced* / Q000378:metabolism; D013928:Thromboxane A2 / Q000378:metabolism
D052246:Cyclooxygenase 2 Inhibitors; D013928:Thromboxane A2; D011464:Epoprostenol; D015232:Dinoprostone